Back to all Current clinical trials
Back to all Current clinical trials
Pefozafermin: Treatment for advanced fatty liver disease (cirrhosis)
Patients will be treated with an subcutaneous injection of pefozafermin or placebo for fatty liver disease advanced. Injections every one to two weeks. Prior studies have shown benefit.
What you need to know
Who can take part?
- 18 - 75
- BMI 25-50
- Cirrhosis of the liver from MASH
- Exclusion
- Fibrosis of the liver
- any other liver disease
- T2DM uncontrolled or T1DM
What is involved for me?
Up to 12 week screening period which will include medical and medication history, scans and possible liver biopsy.
Trial dates
December 2024 - June 2026
